Autologous tumor vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2023 (NCT05807035)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06868433 | Phase 1 | May 8, 2025 | Emory University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT05807035 | Phase 1 | Feb 10, 2023 | Australian Respiratory and Sleep Medicine Institute, Vaxine Pty Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Australian Respiratory and Sleep Medicine Institute | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
| Vaxine Pty Ltd | For profit | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1